Summer 2026

Software Engineering Intern

Multiple Teams

Posted on 8/1/2025

Deadline 10/13/25
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$29 - $33.25/hr

No H1B Sponsorship

North Haven, CT, USA + 2 more

More locations: Lafayette, CO, USA | Minneapolis, MN, USA

Hybrid

Interns must work a minimum of 4 days a week onsite.

Category
Software Engineering (5)
, , , ,
Requirements
  • Working towards a bachelor’s or master’s degree in computer or software engineering, computer science or related engineering major with an anticipated graduation date of Winter 2026, Spring 2027, Winter 2027 or Spring 2028
  • The ability to participate full time (40 hours/week) as part of our intern cohort from June 1 - August 14 (semester system programs) or June 15 – August 21 (quarter system programs)
  • Legally authorized to work in the U.S. on a full-time basis and do not require sponsorship in the future for an employment visa. The Medtronic Summer Internship Program does not provide work authorization sponsorship for summer intern positions. Individuals with temporary visas such as E, F-1, H-1, H-2, L, B, J or TN, or who need sponsorship for work authorization now or in the future, are not eligible for the Medtronic Summer Internship Program.
Desired Qualifications
  • A minimum 3.0 out of a 4.0 cumulative GPA
  • Flexibility in geographic location
  • Knowledge of one or more of the following technologies: C, C++, C#/.NET, SQL, JavaScript, Java, Swift, HTML/CSS, Microsoft Visual Studio, Jenkins, Gitlab
  • Prior work on projects in a team environment
  • Relevant academic project, internship, or lab experience
  • Experience in statistics and data analysis and/or Design for Reliability and Manufacturability (DRM)
  • Technical writing skills
  • Strong written and verbal communication skills who is self-motivated, proactive, and willing to learn

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Your Connections

People at Medtronic who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PulseSelect and Affera are driving strong electrophysiology growth.
  • MiniMed separation can sharpen capital allocation and improve portfolio focus.
  • ICE investments could strengthen Affera with real-time imaging differentiation.

What critics are saying

  • Boston Scientific and Abbott can compress pricing across electrophysiology.
  • Structural heart competition from Edwards Lifesciences threatens valve procedure share.
  • MiniMed separation creates execution risk and investor scrutiny if growth disappoints.

What makes Medtronic unique

  • Global scale spans cardiovascular, neuroscience, medical surgical, and diabetes portfolios.
  • Integrated procedural ecosystems combine devices, imaging, mapping, and monitoring around clinical workflows.
  • Acquisitions and R&D consistently expand technology depth and market access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
OC Academy
Jun 18th, 2026
Medtronic launches PulseSelect PFA system in India.

Medtronic launches PulseSelect PFA system in India. Recently, Medtronic expanded its cardiac portfolio by introducing the PulseSelect system in India. Consequently, Indian cardiologists now have access to this next-generation pulsed field ablation technology to treat atrial fibrillation. Atrial fibrillation remains a severely underdiagnosed heart rhythm disorder that affects millions of people across the country. However, traditional thermal therapies like radiofrequency ablation often carry a small risk of collateral tissue damage. To solve this issue, the novel system delivers short electrical pulses instead of extreme heat or cold. This non-thermal mechanism successfully isolates the pulmonary veins while protecting nearby sensitive structures. How Pulsed Field Ablation enhances patient safety. Specifically, the system targets cardiac cells using a high-voltage electrical field. Because it avoids thermal energy, it prevents injury to the esophagus and surrounding nerves. Therefore, physicians can perform the procedure more safely and quickly than before. In addition, clinical studies have already demonstrated the system's exceptional safety profile globally. Meanwhile, Indian hospitals are already integrating this breakthrough into their routine electrophysiology workflows. Addressing the Growing Burden of AFib in India. India is witnessing a significant rise in stroke cases and complex cardiac diseases. As a result, expanding advanced therapeutic options is critical for improving patient outcomes. Furthermore, many patients ignore mild symptoms, which unfortunately delays their diagnosis and care. Medtronic aims to bridge this care gap by supporting healthcare providers with high-precision tools. Ultimately, this innovation will help reduce stroke risks and enhance the overall quality of life for those pursuing an advanced career in cardiology. Frequently asked questions. Q1: What is pulsed field ablation? Pulsed field ablation is a non-thermal cardiac ablation technique that uses controlled electrical pulses to target abnormal heart tissue while sparing adjacent structures. Q2: How does the PulseSelect system reduce procedural risks? The device avoids extreme temperatures, which significantly lowers the risk of damaging nearby tissues like the esophagus or phrenic nerve. References * Medtronic launches device to treat atrial fibrillation - ETHealthworld * Medtronic Introduces PulseSelect(TM) PFA Technology to address India's Growing AFib and Stroke Burden - Medtronic Press Release * Kauvery Hospitals Launches Advanced Pulsed Field Ablation Systems in Chennai for Atrial Fibrillation Treatment in Tamil Nadu - ANI News Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.

Idaho Urologic Institute
Jun 12th, 2026
Congratulations to Dr. Katharina Mitchell on successfully completing her first AltaViva implant!

Congratulations to Dr. Katharina Mitchell on successfully completing her first AltaViva implant! At Idaho Urologic Institute and Surgery Centr of Idaho, Idurology is committed to offering innovative treatment options that improve the quality of life for its patients. Idurology is proud to have several urologists trained in this advanced therapy, expanding access to care for patients experiencing overactive bladder and related urinary conditions. Idurology is grateful for its partnership with Medtronic and the opportunity to bring leading-edge technology and treatment options to the communities Idurology serve. Collaborations like these help ensure its patients have access to the latest advancements in urologic care close to home. Thank you to everyone involved in supporting this milestone. Idurology look forward to continuing to grow these services and helping more patients find relief and improve their daily lives.

Investing.com
Jun 3rd, 2026
Medtronic invests in two ICE catheter technology companies By Investing.com

Medtronic invests in two ICE catheter technology companies

Yahoo Finance
Apr 10th, 2026
GE HealthCare and Medtronic launch integrated neurosurgery imaging and navigation system

Medtronic and GE HealthCare have launched a digital integration combining GE's bkActiv intraoperative ultrasound with Medtronic's Stealth AXiS surgical navigation system for cranial neurosurgery. The commercially available system provides real-time imaging during procedures, connecting Medtronic's navigation and robotics platforms with GE HealthCare's imaging technology. The integration aims to enhance clinical decision-making during complex cranial procedures through precise guidance and visualisation. It may influence hospital equipment purchasing decisions, surgeon productivity and operating room efficiency. Medtronic currently trades at $87.91, approximately 19.8% below the $109.64 analyst target range midpoint. The stock has experienced a 2.2% decline over the past 30 days. Adoption rates amongst surgeons and hospitals, alongside hospital capital spending on neurosurgery suites, will be key factors to monitor.

The Associated Press
Apr 9th, 2026
GE HealthCare integrates bkActiv ultrasound with Medtronic Stealth AXiS for real-time cranial surgery navigation

GE HealthCare has announced a digital integration between its bkActiv intraoperative ultrasound system and Medtronic's Stealth AXiS surgical navigation system, now commercially available for cranial procedures. The integration allows neurosurgeons to use bkActiv as a plug-and-play real-time visualisation solution during procedures. The system addresses "brain shift", a natural movement of the brain during surgery that reduces pre-surgical image accuracy. bkActiv provides live ultrasound images alongside pre-operative MRI or CT scans on the Stealth AXiS system, recently cleared by the FDA for cranial procedures in the United States. Features include sterilisable transducers, sensitive colour Doppler for blood flow visualisation, and remote control capability from the sterile field. The companies will showcase the integration at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026.

INACTIVE